IMR Press / EJGO / Volume 23 / Issue 2 / pii/2002125

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Original Research

Concurrent radiotherapy and weekly paclitaxel for locally advanced or recurrent squamous cell carcinoma of the uterine cervix. A pilot study with intensification of dose

Show Less
1 Division CJ/Radiotherapy A, Istituto Na?ionale Tumori, Milan(Italy)
2 Division of Gynecologic Oncology, Istituto Na?ionale Tumori, Milan (Italy)
3 Division of Preventive Medicine, Istituto Na?ionale Tumori, Milan (Italy)
4 Division of Radiology A, Istituto Na?ionale Tumori, Milan (Italy)
5 Institute of Radiology, University of Milan, Milan (Italy)
Eur. J. Gynaecol. Oncol. 2002, 23(2), 115–119;
Published: 10 April 2002
Abstract

Objective: This study included patients with inoperable primary or recurrent cervical cancer whose treatment plan called for exclu­sive radiotherapy. The endopoints of the study were to confirm the feasibility of concurrent radiotherapy and paclitaxel in relation to potential acute toxicity and to evaluate if an increase of complete local control might be obtained with the association of pacli­taxel to radiotherapy as a radiosensitizer. Methods: Twenty patients (13 new cases, stage IIB-III, and 7 with pelvic recurrences) were enrolled and, with exclusion of one recurrence, 19 were evaluable for acute toxicity and response. In new cases, radiotherapy was conventionally administered: 50.4 Gy/28 fractions by external beam (whole pelvis) followed by intracavitary cesium or reduced transcutaneous field. In recurrences, radiotherapy was performed with external beam only through individualized fields. Paclitaxel was administered weekly at the dose of 40 mg/m2 or 60 mg/m2 during the entire course of external radiotherapy. Results: Complete regression (CR) as defined by clinical and imaging examinations was achieved in eight of the 13 new cases (62%) and in four of the six recurrences (66%), for a total complete response rate equal to 63%. Five patients (3 treated with 40 mg/m2 and 2 with 60 mg/m2) experienced grade 3 small bowel toxicity, one patient treated with 40 mg/m2 grade 3 bladder toxicity and one patient treated with 60 mg/m2 had grade 4 mucositis. Out of 12 CR patients at the end of treatment, ten maintain complete local remission for a median follow-up of 47 months but two have developed distant metastases. Conclusion: The results confirm that this approach is feasible and suggest the use of paclitaxel as radiosensitizer in locally advan­ced cervical cancer.

Keywords
Paclitaxel
Radiosensitizer
Cervical cancer
Share
Back to top